Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2014

01-02-2014 | Original Article

Cyclooxygenase-2 Expression Is Associated with Poor Overall Survival of Patients with Gastric Cancer: A Meta-Analysis

Authors: Jian Song, Hong Su, Yang-yang Zhou, Liang-liang Guo

Published in: Digestive Diseases and Sciences | Issue 2/2014

Login to get access

Abstract

Background

Cyclooxygenase-2 (COX-2) is believed to be involved in gastric carcinogenesis. However, it is still controversial whether COX-2 expression can be regarded as a prognostic factor for gastric cancer patients.

Aim

To obtain a more accurate relationship between COX-2 overexpression and prognosis in gastric cancer by meta-analysis.

Method

Relevant articles published up to May 2013 were searched by use of several keywords in electronic databases. Separate hazard ratio (HR) estimates and 95 % confidence intervals (95 % CI) for COX-2 overexpression and overall survival (OS) and disease-free survival (DFS) with gastric cancer were extracted. Combined HR with 95 % CI was calculated by use of Stata11.0 software to estimate the size of the effect. Publication bias testing and sensitivity analysis were also performed.

Results

A total of 27 studies which included 3,891 gastric cancer patients were combined in the final analysis. Combined results suggested that COX-2 overexpression was associated with an unfavorable OS (HR 1.58, 95 % CI 1.36–1.84) but not DFS (HR 1.15, 95 % CI 0.93–1.43) among patients with gastric cancer. Publication bias was absent. Sensitivity analysis suggested that the results of this meta-analysis were robust.

Conclusions

The results of this meta-analysis suggest that high COX-2 expression may be an independent risk factor for poor OS of patients with gastric cancer. More large prospective studies are now needed to further clarify the prognostic value of COX-2 expression for DFS in gastric cancer.
Literature
1.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–2917.PubMedCrossRef
2.
Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14:249–258.PubMed
3.
Xing X, Tang YB, Yuan G, et al. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer. 2013;132:2589–2596.PubMedCrossRef
4.
Zhang QW, Liu L, Chen R, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:2903–2908.PubMedCrossRef
5.
Peng L, Zhan P, Zhou Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39:9473–9484.PubMedCrossRef
6.
Thiel A, Mrena J, Ristimäki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev. 2011;30:387–395.PubMedCrossRef
7.
Wu WK, Sung JJ, Lee CW, et al. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010;295:7–16.PubMedCrossRef
8.
Fujimura T, Ohta T, Oyama K, et al. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol. 2006;12:1336–1345.PubMed
9.
Oshima H, Oshima M, Inaba K, et al. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669–1678.PubMedCrossRef
10.
Thiel A, Narko K, Heinonen M, et al. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer. 2012;131:1032–1041.PubMedCrossRef
11.
Jiang H, Wang J, Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. Clin Chim Acta. 2013;419:26–32.PubMedCrossRef
12.
Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol. 2013;129:613–619.PubMedCrossRef
13.
Huang M, Chen Q, Xiao J, et al. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer. 2013;132:363–373.PubMedCrossRef
14.
Almeida PR, Ferreira FV, Santos CC, et al. Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases. World J Gastroenterol. 2012;18:778–784.PubMedCrossRef
15.
Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003;37:28–33.PubMedCrossRef
16.
Tang H, Wang J, Bai F, et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008;26:60–67.PubMedCrossRef
17.
Zhang X, Wu Q, Gan L, et al. Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer. Med Oncol. 2013;30:454.PubMedCrossRef
18.
Jiang H, Qiao XL, Huang FY. Expressions and clinical significance of Smad4 and Cox-2 in gastric cancer. J Clin Med Pract. 2012;16:30–33.
19.
Fanelli MF, Chinen LT, Begnami MD, et al. The influence of transforming growth factor-a, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial–mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61:153–161.PubMedCrossRef
20.
Gou HF, Chen XC, Zhu J, et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011;30:14.PubMedCrossRef
21.
Zhang C, Wang XQ, Xu C, et al. Expression of cyr-61 and cox-2 in gastric carcinoma and its clinical significance. J China Med Univ. 2011;40:744–748.
22.
Sun GY, Luo DH, Wu JS, et al. The expression of NICD and COX-2 in gastric carcinoma tissues and its clinical biological significance. J Med Res. 2011;40:61–66.
23.
Tatsuwaki H, Tanigawa T, Watanabe T, et al. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci. 2010;101:550–558.PubMedCrossRef
24.
Mrena J, Wiksten JP, Kokkola A, et al. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010;31:1–7.PubMedCrossRef
25.
Li Y, Tan BB, Fan LQ, et al. Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis. Hepatogastroenterology. 2010;57:1435–1441.PubMed
26.
Zhai JH, Li N, Zhang L, et al. Expression of P16, C-MYC and COX-2 in gastric carcinoma and relationship with the prognosis of patients. J Zhejiang Coll Tradit Chin Med. 2009;33:321–322.
27.
Yamac D, Ayyildiz T, Coskun U, et al. Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol Res Pract. 2008;204:527–536.PubMedCrossRef
28.
Ye SC, Wang JY, Yuan GZ, et al. Expression of COX-2 and P-gp and its prognosis in gastric carcinoma. Chin Gen Pract. 2008;11:291–294.
29.
Lazar D, Taban S, Ardeleanu C, et al. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients’ survival. Rom J Morphol Embryol. 2008;49:371–379.PubMed
30.
Kolev Y, Uetake H, Takagi Y, et al. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol. 2008;15:2336–2344.PubMedCrossRef
31.
Da MX, Wu XT, Wang J, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39:92–99.PubMedCrossRef
32.
Gudis K, Tatsuguchi A, Wada K, et al. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum Pathol. 2007;38:1826–1835.PubMedCrossRef
33.
Li M, Liu W, Zhu YF, et al. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta Oncol. 2006;45:1115–1119.PubMedCrossRef
34.
35.
Linder N, Haglund C, Lundin M, et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol. 2006;59:965–971.PubMedCrossRef
36.
Yu JR, Wu YJ, Qin Q, et al. Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis. World J Gastroenterol. 2005;11:4908–4911.PubMed
37.
Okano H, Shinohara H, Miyamoto A, et al. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clin Cancer Res. 2004;10:6938–6945.PubMedCrossRef
38.
Shi H, Xu JM, Hu NZ, et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421–1426.PubMed
39.
Joo YE, Oh WT, Rew JS, et al. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002;66:222–229.PubMedCrossRef
40.
Leung WK, To KF, Ng YP, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84:335–339.PubMedCentralPubMedCrossRef
41.
Lee TL, Leung WK, Lau JY, et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Lett. 2001;168:133–140.PubMedCrossRef
42.
Chen CN, Sung CT, Lin MT, et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001;233:183–188.PubMedCrossRef
43.
Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519–525.PubMed
44.
Nordmann AJ, Kasenda B, Briel M. Meta-analyses: what they can and cannot do. Swiss Med Wkly. 2012;142:w13518.PubMed
45.
McShane LM, Altman DG, Sauerbrei W. Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol. 2006;28:99–105.PubMed
46.
Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–1134.PubMedCrossRef
47.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7:8–16.
48.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834.PubMedCrossRef
49.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.PubMedCrossRef
50.
Zhao HC, Qin R, Chen XX, et al. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol. 2006;12:7598–7603.PubMed
51.
Han SL, Tang HJ, Hua YW, et al. Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg. 2003;20:107–114.PubMedCrossRef
52.
Al-Moundhri MS, Al-Hadabi I, Al-Mawaly K, et al. Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. Med Oncol. 2012;29:1739–1747.PubMedCrossRef
53.
Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006;243:64–73.PubMedCrossRef
54.
Vidal O, Soriano-Izquierdo A, Pera M, et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg. 2008;12:1005–1014.PubMedCrossRef
55.
Mrena J, Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11:7362–7368.PubMedCrossRef
56.
Mrena J, Wiksten JP, Nordling S, et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59:618–623.PubMedCrossRef
57.
Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007;14:2738–2747.PubMedCrossRef
58.
Jamieson NB, Carter CR, McKay CJ, et al. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17:3316–3331.PubMedCrossRef
59.
Li L, Zhao J, Wu Z, et al. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther. 2009;30:589–596.PubMedCrossRef
60.
Peng L, Zhou Y, Wang Y, et al. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS ONE. 2013;8:e58891.PubMedCentralPubMedCrossRef
61.
62.
Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol. 2004;35:488–495.PubMedCrossRef
63.
Sun WH, Sun YL, Fang RN, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol. 2005;35:707–713.PubMedCrossRef
64.
Lukaszewicz-Zając M, Mroczko B, Szmitkowski M. Gastric cancer—the role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011;412:1725–1730.PubMedCrossRef
65.
Gamba CA, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the women’s health initiative. Cancer. 2013;119:1562–1569.PubMedCrossRef
66.
Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:34–39.PubMedCrossRef
67.
Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55:1533–1539.PubMedCrossRef
68.
Yu J, Tang BD, Leung WK, et al. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol. 2005;11:41–45.PubMed
69.
Liu H, Huang P, Xu X, et al. Anticancer effect of celecoxibvia COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci. 2009;54:1418–1424.PubMedCrossRef
70.
Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther. 2003;2:140–149.CrossRef
71.
Russo A, Bazan V, Migliavacca M, et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res. 2000;6:178–184.PubMed
Metadata
Title
Cyclooxygenase-2 Expression Is Associated with Poor Overall Survival of Patients with Gastric Cancer: A Meta-Analysis
Authors
Jian Song
Hong Su
Yang-yang Zhou
Liang-liang Guo
Publication date
01-02-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2917-1

Other articles of this Issue 2/2014

Digestive Diseases and Sciences 2/2014 Go to the issue

Original Article

Translation and Psychometric Evaluation of the Chinese Version of Functional Digestive Disorders Quality of Life Questionnaire

Review

Measures to Reduce Mother-to-Child Transmission of Hepatitis B Virus in China: A Meta-Analysis

Original Article

Prognostic Factors for Successful Endoscopic Transpapillary Drainage of Pancreatic Pseudocysts

Original Article

The Risk Factors for Discrepancy After Endoscopic Submucosal Dissection of Gastric Category 3 Lesion (Low Grade Dysplasia)

Original Article

High Serum Vaspin Concentrations in Patients with Ulcerative Colitis

Original Article

Chemokine–Chemokine Receptor CCL2–CCR2 and CX3CL1–CX3CR1 Axis May Play a Role in the Aggravated Inflammation in Primary Biliary Cirrhosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits